GENE EDITING 101
All Companies
🇫🇷

Cellectis

Public

TALEN pioneers for off-the-shelf CAR-T

Cellectis is a clinical-stage biopharmaceutical company and pioneer of TALEN gene editing technology. Based in Paris, the company develops allogeneic (off-the-shelf) CAR-T cell therapies using its proprietary TALEN platform, enabling universal donor-derived cancer treatments.

Founded1999
HQParis, France
CEOAndré Choulika
TickerNASDAQ:CLLS
Total Funding$800M

Pipeline

Drug / ProgramIndicationPhaseTechnology
UCART123Acute Myeloid LeukemiaPhase 1TALEN
UCART22B-ALLPhase 1TALEN
UCARTCS1Multiple MyelomaPhase 1TALEN

Key People

André ChoulikaCEO & Founder